Leadership & Pay ·
DexCom appoints former Stryker CFO Glenn Boehnlein to its Board of Directors
DXCMDexcom Inc
On September 10, 2026, DexCom, Inc. announced the appointment of Glenn S. Boehnlein to its Board of Directors, effective immediately. The Board increased its size to thirteen directors and assigned Mr. Boehnlein to the Operations & Innovation Committee and the Audit Committee. Upon appointment, he received an initial equity grant of restricted stock units with a fair value of $500,000, vesting annually over three years. Mr. Boehnlein brings extensive healthcare executive experience, having most recently served as Vice President and Chief Financial Officer at Stryker Corporation from 2016 to 2025. He currently serves on the boards of Inogen, Inc., Agilent Technologies, Inc., and Sutter Health. DexCom operates in the medical technology industry, specializing in glucose biosensing technology for diabetes management.